These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 8773479)
1. Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy. Cohen MP; Clements RS; Hud E; Cohen JA; Ziyadeh FN Exp Nephrol; 1996; 4(3):166-71. PubMed ID: 8773479 [TBL] [Abstract][Full Text] [Related]
2. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice. Cohen MP; Lautenslager GT; Shearman CW Metabolism; 2001 Dec; 50(12):1435-40. PubMed ID: 11735089 [TBL] [Abstract][Full Text] [Related]
3. Effect of varied protein intake on the nephropathy of the diabetic mouse (C57BL/s J db/db). Brouhard BH; Rajaraman S; LaGrone LF Int J Pediatr Nephrol; 1987; 8(2):59-68. PubMed ID: 3308729 [TBL] [Abstract][Full Text] [Related]
4. Diabetic kidney disease in the db/db mouse. Sharma K; McCue P; Dunn SR Am J Physiol Renal Physiol; 2003 Jun; 284(6):F1138-44. PubMed ID: 12736165 [TBL] [Abstract][Full Text] [Related]
5. Studies of the glomerular mesangium and the juxtaglomerular apparatus in the genetically diabetic mouse. Bower G; Brown DM; Steffes MW; Vernier RL; Mauer SM Lab Invest; 1980 Oct; 43(4):333-41. PubMed ID: 7003252 [TBL] [Abstract][Full Text] [Related]
6. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice. Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690 [TBL] [Abstract][Full Text] [Related]
7. Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy. Mima A; Arai H; Matsubara T; Abe H; Nagai K; Tamura Y; Torikoshi K; Araki M; Kanamori H; Takahashi T; Tominaga T; Matsuura M; Iehara N; Fukatsu A; Kita T; Doi T Diabetes; 2008 Jun; 57(6):1712-22. PubMed ID: 18285555 [TBL] [Abstract][Full Text] [Related]
8. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Zheng F; He C; Cai W; Hattori M; Steffes M; Vlassara H Diabetes Metab Res Rev; 2002; 18(3):224-37. PubMed ID: 12112941 [TBL] [Abstract][Full Text] [Related]
9. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes. Moriyama T; Oka K; Ueda H; Imai E Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900 [TBL] [Abstract][Full Text] [Related]
10. 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Ichinose K; Maeshima Y; Yamamoto Y; Kinomura M; Hirokoshi K; Kitayama H; Takazawa Y; Sugiyama H; Yamasaki Y; Agata N; Makino H Diabetes; 2006 May; 55(5):1232-42. PubMed ID: 16644677 [TBL] [Abstract][Full Text] [Related]
11. Prevention of decline in renal function in the diabetic db/db mouse. Cohen MP; Clements RS; Cohen JA; Shearman CW Diabetologia; 1996 Mar; 39(3):270-4. PubMed ID: 8721771 [TBL] [Abstract][Full Text] [Related]
12. Diffuse glomerulosclerosis without tubular injury does not directly manifest renal dysfunction in nephrotic mice (ICGN strain). Mizuno S; Yue BF; Okamoto M; Horikawa Y; Kurosawa T Exp Nephrol; 1997; 5(6):498-507. PubMed ID: 9438179 [TBL] [Abstract][Full Text] [Related]
13. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Flyvbjerg A; Dagnaes-Hansen F; De Vriese AS; Schrijvers BF; Tilton RG; Rasch R Diabetes; 2002 Oct; 51(10):3090-4. PubMed ID: 12351452 [TBL] [Abstract][Full Text] [Related]
15. A sensitized screen of N-ethyl-N-nitrosourea-mutagenized mice identifies dominant mutants predisposed to diabetic nephropathy. Tchekneva EE; Rinchik EM; Polosukhina D; Davis LS; Kadkina V; Mohamed Y; Dunn SR; Sharma K; Qi Z; Fogo AB; Breyer MD J Am Soc Nephrol; 2007 Jan; 18(1):103-12. PubMed ID: 17151334 [TBL] [Abstract][Full Text] [Related]
16. Aerobic training and diabetic nephropathy in the obese Zucker rat. Ward KM; Mahan JD; Sherman WM Ann Clin Lab Sci; 1994; 24(3):266-77. PubMed ID: 8048799 [TBL] [Abstract][Full Text] [Related]
17. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Ito T; Tanimoto M; Yamada K; Kaneko S; Matsumoto M; Obayashi K; Hagiwara S; Murakoshi M; Aoki T; Wakabayashi M; Gohda T; Funabiki K; Maeda K; Horikoshi S; Tomino Y Nephrology (Carlton); 2006 Feb; 11(1):29-35. PubMed ID: 16509929 [TBL] [Abstract][Full Text] [Related]
18. Glomerular lesions in nonobese diabetic mouse: before and after the onset of hyperglycemia. Doi T; Hattori M; Agodoa LY; Sato T; Yoshida H; Striker LJ; Striker GE Lab Invest; 1990 Aug; 63(2):204-12. PubMed ID: 2199727 [TBL] [Abstract][Full Text] [Related]
19. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. Chow FY; Nikolic-Paterson DJ; Ozols E; Atkins RC; Tesch GH J Am Soc Nephrol; 2005 Jun; 16(6):1711-22. PubMed ID: 15857924 [TBL] [Abstract][Full Text] [Related]
20. Up-regulation of protease-activated receptor-1 in diabetic glomerulosclerosis. Sakai T; Nambu T; Katoh M; Uehara S; Fukuroda T; Nishikibe M Biochem Biophys Res Commun; 2009 Jun; 384(2):173-9. PubMed ID: 19401193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]